Financial Results + Capacity Expansion

Balaji Amines Reports Strong Q4FY26 Performance; Announces ₹750 Crore Specialty Chemicals Expansion

NSE

balamines

BSE

530999

Balaji Amines Limited reported strong Q4FY26 operational performance with consolidated revenue of ₹403 crore, EBITDA of ₹102 crore, and PAT of ₹65 crore. The company also announced a phased ₹750 crore expansion plan for Balaji Specialty Chemicals Limited.

PRICE-SENSITIVE TRIGGER

Event: Q4FY26 & FY26 Financial Results with Expansion Announcement

Type: Financial Results + Capacity Expansion

Impact: Positive

Immediate Effect: Improved profitability, higher EBITDA margins, and aggressive specialty chemicals expansion strengthen Balaji Amines’ long-term growth outlook.

Key Metrics:

Q4FY26 Consolidated Revenue: ₹403 Crore
Q4FY26 EBITDA: ₹102 Crore
Q4FY26 EBITDA Margin: 25%
Q4FY26 PAT: ₹65 Crore
Q4FY26 Sales Volume: 27,341 MT
FY26 Consolidated Revenue: ₹1,454 Crore
FY26 Consolidated EBITDA: ₹294 Crore
FY26 Consolidated PAT: ₹169 Crore
Expansion Investment Planned: ₹750 Crore
Standalone Debt Position: Zero Debt

Highlight:

Label: Major Expansion & Margin Growth
Value: ₹750 Crore specialty chemicals expansion with Q4 EBITDA margin at 25%

What Happened ?

Balaji Amines Limited announced its audited Q4FY26 and FY26 results, reporting strong operational growth and margin improvement across its amines and specialty chemicals businesses.

The company posted consolidated Q4FY26 revenue of ₹403 crore, EBITDA of ₹102 crore, and PAT of ₹65 crore. EBITDA margin improved sharply to 25% compared to 19% in Q4FY25.

Alongside the financial results, Balaji Amines announced a phased ₹750 crore expansion plan through subsidiary Balaji Specialty Chemicals Limited. The Maharashtra government has granted Mega Project status for the proposed expansion under the PSI 2019 scheme.

key highlights

Operational Performance & Expansion Plans:

Q4FY26 consolidated revenue stood at ₹403 crore.
Consolidated EBITDA increased to ₹102 crore with 25% EBITDA margin.
Consolidated PAT for Q4FY26 stood at ₹65 crore.
Total Q4FY26 sales volume increased to 27,341 MT.
The company remains debt-free on a standalone basis.
Balaji Specialty Chemicals expansion project received Mega Project status from Maharashtra government.
Proposed phased investment for expansion stands at ₹750 crore.
Expansion includes products such as HCN, NaCN, EDTA, and related specialty chemicals.
Unit-II greenfield specialty chemicals project is expected to be commissioned during Q4FY2026-27.
DME, NMM, and Acetonitrile projects are under execution and expected to be commissioned during FY2026-27.
Management highlighted steady ramp-up in electronic-grade DMC and DMF products.

Note:

The expansion strategy is focused on higher-value specialty chemicals and import-substitution opportunities, while leveraging export demand and specialty product diversification.

Risk Analysis

Key Risks

Specialty chemical projects involve execution and commissioning risks.
Geopolitical disruptions may impact raw material availability and exports.
Commodity price fluctuations can affect margins.
Ramp-up of new specialty chemical capacities may take time.
Demand slowdown in end-user industries could impact utilization levels.

Worst Case Scenario

Delays in commissioning projects or sharp margin pressure due to raw material volatility could affect profitability and return ratios.

Risk Level: Medium

Company Commentary

Balaji Amines delivered resilient operational performance during FY26 despite temporary external disruptions.
The company maintained stable plant operations through prudent inventory planning and uninterrupted raw material availability.
Management stated that electronic-grade DMC and DMF ramp-up continues to strengthen higher-value business segments.
The company remains focused on improving plant utilization and operational leverage.
Expansion projects are expected to gradually strengthen specialty chemicals capabilities and export opportunities.

Official Exchange Filing: Balaji Amines Limited